Article

Efficacy of futibatinib, an irreversible fibroblast growth factor receptor inhibitor, in FGFR-altered breast cancer

2022-11-18

Abstract excerpt

<title>Abstract</title><p>The role of the fibroblast growth factor receptor (FGFR) gene alterations as therapeutic targets in breast cancer have not been well characterized. Futibatinib (TAS-120; Taiho) is a novel pan-FGFR inhibitor. We sought to determine the efficacy of futibatinib in breast cancer models with<italic>FGFR</italic>alterations. Nine breast cancer patient–derived xenografts (PDXs) with a variety of...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 4f6c765a-8452-5d2d-8560-cc41d02f32ce
DOI: 10.21203/rs.3.rs-2248209/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Efficacy of futibatinib, an irreversible fibroblast growth factor receptor inhibitor, in FGFR-altered breast cancerDOI 10.21203/rs.3.rs-2248209/v1Read

Rationale for targeting fibroblast growth factor receptor signaling in breast cancer.Semantic proximity Read

Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancerSemantic proximity Read

Current Status of Fibroblast Growth Factor Receptors Targeted Therapies in Breast CancerSemantic proximity Read

Genomic correlates of response and resistance to the irreversible FGFR1-4 inhibitor futibatinib based on biopsy and circulating tumor DNA profiling.Semantic proximity Read

Evaluation of FGFR targeting in breast cancer through interrogation of patient-derived models.Semantic proximity Read

Understanding and Overcoming Resistance to Selective FGFR Inhibitors across FGFR2-Driven Malignancies.Semantic proximity Read

FGFR4: A promising therapeutic target for breast cancer and other solid tumors.Semantic proximity Read

FGFR gene amplification and response to HER2-targeted therapy in patients with HER2-expressing metastatic breast cancerSemantic proximity Read

Selective degradation of FGFR1/2 overcomes antiestrogen resistance in ER+ breast cancer with FGFR1/2 alterations.Semantic proximity Read

FGFR a promising druggable target in cancer: Molecular biology and new drugs.Semantic proximity Read

Future applications of FGF/FGFR inhibitors in cancer.Semantic proximity Read

Challenges and opportunities in the targeting of fibroblast growth factor receptors in breast cancer.Semantic proximity Read